Publications by authors named "Sen Zhuang"

Claim this Profile
P
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, Weijun Fu, Jianda Hu, Sen Hong Zhuang

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Jesus G Berdeja, Deepu Madduri, Saad Z Usmani, Andrzej Jakubowiak, Mounzer Agha, Sen Hong Zhuang

Lancet· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Efstathios Kastritis, Giovanni Palladini, Monique C Minnema, Ashutosh D Wechalekar, Arnaud Jaccard, Sen H Zhuang

N Engl J Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Philippe Moreau, Michel Attal, Cyrille Hulin, Bertrand Arnulf, Karim Belhadj, Sen Zhuang

Lancet· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Anas Younes, Laurie H Sehn, Peter Johnson, Pier Luigi Zinzani, Xiaonan Hong, Sen Hong Zhuang

J Clin Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Urte Gayko, Mann Fung, Fong Clow, Steven Sun, Elizabeth Faust, Sen Hong Zhuang

Ann N Y Acad Sci· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Michael Hallek, Neil E Kay, Anders Osterborg, Asher A Chanan-Khan, Michelle Mahler, Sen Hong Zhuang

Future Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors.
Josep Tabernero, Luc Dirix, Patrick Schöffski, Andrés Cervantes, Jose Antonio Lopez-Martin, Sen Hong Zhuang

Clin Cancer Res· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.
Joan Bladé, Pieter Sonneveld, Jesús F San Miguel, Heather J Sutherland, Roman Hajek, Sen H Zhuang

Clin Lymphoma Myeloma Leuk· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.
Gabriele Buda, Deborah Ricci, C Chris Huang, Reyna Favis, Nadine Cohen, Sen H Zhuang

Ann Hematol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy.
Sen H Zhuang, Liang Xiu, Yusri A Elsayed

Cancer J· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.
Hui Huang, Michael Menefee, Maureen Edgerly, Sen Zhuang, Herb Kotz

Clin Cancer Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.
Joseph A Sparano, Anatoly N Makhson, Vladimir F Semiglazov, Sergei A Tjulandin, Olga I Balashova, Sen H Zhuang

J Clin Oncol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
Joan Bladé, Pieter Sonneveld, Jesús F San Miguel, Heather J Sutherland, Roman Hajek, Sen H Zhuang

Clin Lymphoma Myeloma· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Pieter Sonneveld, Roman Hajek, Arnon Nagler, Andrew Spencer, Joan Bladé, Sen H Zhuang

Cancer· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence for microtubule target engagement in tumors of patients receiving ixabepilone.
Sen H Zhuang, Y Elizabeth Hung, Laura Hung, Robert W Robey, Dan L Sackett

Clin Cancer Res· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Robert Z Orlowski, Arnon Nagler, Pieter Sonneveld, Joan Bladé, Roman Hajek, Sen H Zhuang

J Clin Oncol· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.
Sen H Zhuang, Manish Agrawal, Maureen Edgerly, Susan Bakke, Herb Kotz

Cancer· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate cancer metastatic to skin.
Gregory D Leonard, Sen H Zhuang, William Dahut

Urology· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancer.
Gregory D Leonard, Sen H Zhuang, Jean L Grem

J Clin Oncol· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oophorectomy in carriers of BRCA mutations.
Sen H Zhuang, Gregory D Leonard, Sandra M Swain

N Engl J Med· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis